NCT01867307View on ClinicalTrials.gov

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Diabetes Mellitus, Type 2Healthy
Interventions
DRUG

Empagliflozin

DRUG

BI 10773

open label

Trial Locations (1)

Unknown

Boehringer Ingelheim Investigational Site, San Antonio

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY